Patient Selection and Clinic Workflow Considerations for Nalirifox in Metastatic Pancreatic Ductal Adenocarcinoma

This segment examines how patient characteristics and operational considerations intersect when selecting Nalirifox versus FOLFIRINOX for metastatic pancreatic ductal adenocarcinoma. Faculty describe the clinical profiles of patients they believe are most likely to benefit from Nalirifox, including considerations related to performance status, comorbidities, and treatment goals.

The discussion then shifts to practical workflow considerations, such as infusion time, premedication requirements, scheduling, and post infusion monitoring. Panelists explain how these factors influence regimen feasibility in real world clinic settings.

Faculty emphasize that successful treatment selection requires alignment between patient suitability and clinic workflows and operational feasibility. Thoughtful planning around workflow and supportive care infrastructure is described as essential for delivering complex combination regimens safely and efficiently.